Pharmacotherapy and health care costs among patients with schizophrenia and newly diagnosed diabetes

Psychiatric Services

Volumn 56, Issue 7, 2005, Pages 803-809

  Leslie, Douglas L ^a,b,d   Rosenheck, Robert A ^a,c  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^c Education   (United States)

^d NEPEC 182 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE;

COMORBIDITY; DIABETES MELLITUS; DISEASE ASSOCIATION; HEALTH CARE COST; HUMAN; MONOTHERAPY; RETROSPECTIVE STUDY; REVIEW; SCHIZOPHRENIA;

ANTIPSYCHOTIC AGENTS; COSTS AND COST ANALYSIS; DIABETES MELLITUS, TYPE 2; DRUG THERAPY; FEMALE; FOLLOW-UP STUDIES; HEALTH CARE COSTS; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SCHIZOPHRENIA; UNITED STATES;

EID: 22044448587     PISSN: 10752730     EISSN: None     Source Type: Journal    
DOI: 10.1176/appi.ps.56.7.803     Document Type: Review

References (29)

1. Kane J, Honigfeld G, Singer J, et al: Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Archives of General Psychiatry 45:789-796, 1988
2. Tollefson GD, Beasley CM Jr, Tran PV, et al: Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. American Journal of Psychiatry 154:457-4 65, 1997
3. Small JG, Hirsch SR, Arvanitis LA, et al: Quetiapine in patients with schizophrenia: a high- and low-dose double-blind comparison with placebo: Seroquel Study Group. Archives of General Psychiatry 54:549-557, 1997
4. Murder SR, Meibach RC: Risperidone in the treatment of schizophrenia. American Journal of Psychiatry 151:825-835, 1994
5. Goff DC, Posever T, Herz L, et al: An exploratory haloperidol-controlled dose-finding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder. Journal of Clinical Psychopharmacology 18:296-304, 1998
6. Potkin SG, Saha AR, Kujawa MJ, et al: Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Archives of General Psychiatry 60:681-690, 2003
7. Marder SR, McQuade RD, Stock E, et al: Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophrenia Research 61:123-136, 2003
8. Stahl SM: Selecting an atypical antipsychotic by combining clinical experience with guidelines from clinical trials. Journal of Clinical Psychiatry 60(suppl 10):31-41, 1999
9. Bustillo JR, Buchanan RW, Irish D, et al: Differential effect of clozapine on weight: a controlled study. American Journal of Psychiatry 153:817-819, 1996
10. Cohen S, Chiles J, MacNaughton A: Weight gain associated with clozapine. American Journal of Psychiatry 147:503-504, 1990
11. Henderson DC, Cagliero E, Gray C, et al: Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: a five-year naturalistic study. American Journal of Psychiatry 157:975-981, 2000
12. Lamberti JS, Bellnier T, Schwarzkopf SB: Weight gain among schizophrenic patients treated with clozapine. American Journal of Psychiatry 149:689-690, 1992
13. Gianfrancesco FD, Grogg AL, Mahmoud RA, et al: Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: findings from a large health plan database. Journal of Clinical Psychiatry 63:920-930, 2002
14. Allison DB, Mentore JL, Heo M, et al: Antipsychotic-induced weight gain: a comprehensive research synthesis. American Journal of Psychiatry 156:1686-1696, 1999
15. Fertig MK, Brooks VG, Shelton PS, et al: Hyperglycemia associated with olanzapine. Journal of Clinical Psychiatry 59:687-689, 1998
16. Ober SK, Hudak R, Rusterholtz A: Hyperglycemia and olanzapine. American Journal of Psychiatry 156:970, 1999
17. Wirshing DA, Spellberg BJ, Erhart SM, et al: Novel antipsychotics and new onset diabetes. Biological Psychiatry 44:778-783, 1998
18. Koro CE, Fedder DO, L'Italien GJ, et al: An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients. Archives of General Psychiatry 59:1021-1026, 2002
19. Sobel M, Jaggers ED, Franz MA: New-onset diabetes mellitus associated with the initiation of quetiapine treatment. Journal of Clinical Psychiatry 60:556-557, 1999
20. Leslie DL, Rosenheck RA: Incidence of newly diagnosed diabetes attributable to atypical antipsychotic medications. American Journal of Psychiatry 161:1709-1711, 2004
21. Rosenheck R, Perlick D, Bingham S, et al: Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia. JAMA 290:2693-2702, 2003
22. Leslie DL, Rosenheck RA: From conventional to atypical antipsychotics and back: dynamic processes in the diffusion of new medications. American Journal of Psychiatry 159:1534-1540, 2002
23. Rosenbaum P, Rubin D: The central role of propensity score in observational studies for causal effects. Biometrika 70:41-55, 1983
24. Rosenbaum P, Rubin D: Reducing bias in observational studies using subclassification on the propensity score. American Statistician 39:33-38, 1984
25. Rosenbaum P, Rubin D: Constructing a control group using multivariate matched sampling methods that incorporate the propensity score. Journal of the American Statistical Association 79:516-524, 1985
26. Rubin DB: Estimating causal effects from large data sets using propensity scores. Annals of Internal Medicine 127:757-763, 1997
27. The logistic procedure, in SAS/STAT User's Guide: Version 8. Cary, NC, SAS Institute, 1999
28. Rosenheck R, Doyle J, Leslie D, et al: Changing environments and alternative perspectives in evaluating the cost-effectiveness of new antipsychotic drugs. Schizophrenia Bulletin 29:81-93, 2003
29. Caro JJ, Ward AJ, O'Brien JA: Lifetime costs of complications resulting from type 2 diabetes in the US. Diabetes Care 25:476-481, 2002